Patients newly diagnosed with breast cancer face a series of complex decisions regarding locoregional and systemic treatment. Currently many of these decisions do not meet the definition of a high quality decision,defined as one that is both informed (i.e., based on an accurate understanding of the treatment risks and benefits) and preference-concordant (i.e., consistent with the patients'underlying preferences). Moreover, the introduction of evaluative tests has made these decisions more complicated for many patients. There is a need to improve the quality of locoregional and systemic treatment decisions for breast cancer patients, and to help patients understand the role of evaluative tests in this decision process. Ensuring patients can deliberate effectively about these decisions, assert their views and communicate with their clinicians is likely to improve their overall decision preparedness and satisfaction. Project 3 will focus on the third pillar of individualized care by evaluating the impact of an innovative decision tool on locoregional and systemic therapy decision making for newly diagnosed breast cancer patients. The innovative online decision tool has been developed and tested over the past two years by the CanSORT team (R21 CA129859). Pilot data suggests that this tool has a positive impact on patient knowledge and decision outcomes. The goal of project 3 is to evaluate the impact of this tool, after it is enhanced in collaboration with our Communication and Dissemination Core, on the quality of decision making for locoregional and systemic breast cancer treatment decision making. We will conduct a randomized controlled trial (RCT) of 444 newly diagnosed patients with invasive early stage breast cancer, seen by 28-30 surgeons in two SEER catchment areas. Patients will be randomized to view our comprehensive decision tool or a

Public Health Relevance

Breast cancer patients make many complex decisions from locoregional through systemic treatment. Ensuring these decisions are high quality is a priority. Project 3 will deploy and evaluate an innovative decision tool designed to improve locoregional and systemic breast cancer treatment decision making. The results can be translated into efforts to improve individualized decicision making for future patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA163233-01A1
Application #
8374173
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (M1))
Project Start
2012-09-01
Project End
2017-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
1
Fiscal Year
2012
Total Cost
$434,618
Indirect Cost
$135,016
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Katz, Steven J; Hawley, Sarah T; Hamilton, Ann S et al. (2018) Surgeon Influence on Variation in Receipt of Contralateral Prophylactic Mastectomy for Women With Breast Cancer. JAMA Surg 153:29-36
Lee, Kamaria L; Janz, Nancy K; Zikmund-Fisher, Brian J et al. (2018) What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment? Med Decis Making 38:95-106
Morrow, Monica; Jagsi, Reshma; McLeod, M Chandler et al. (2018) Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer. JAMA Oncol 4:1511-1516
Radhakrishnan, Archana; Chandler McLeod, M; Hamilton, Ann S et al. (2018) Preferences for Physician Roles in Follow-up Care During Survivorship: Do Patients, Primary Care Providers, and Oncologists Agree? J Gen Intern Med :
Jagsi, Reshma; Ward, Kevin C; Abrahamse, Paul H et al. (2018) Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. Cancer 124:3668-3676
Kurian, Allison W; Ward, Kevin C; Hamilton, Ann S et al. (2018) Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncol 4:1066-1072
Resnicow, Ken; Patel, Minal R; Mcleod, M Chandler et al. (2018) Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty. Breast Cancer Res Treat :
Katz, Steven J; Bondarenko, Irina; Ward, Kevin C et al. (2018) Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. JAMA Surg 153:909-916
Morrow, Monica; Abrahamse, Paul; Katz, Steven J (2018) Trend Analysis on Reoperation After Lumpectomy for Breast Cancer-Reply. JAMA Oncol 4:747
Gornick, Michele C; Kurian, Allison W; An, Lawrence C et al. (2018) Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial. Cancer 124:4000-4009

Showing the most recent 10 out of 47 publications